Thu. 22 Feb 2024, 6:33am ET
Benzinga
Earnings, News
Karuna Therapeutics (NASDAQ:KRTX) reported quarterly losses of $(3.01) per share which missed the analyst consensus estimate of $(2.65) by 13.58 percent. This is a 35.59 percent decrease over losses of $(2.22) per share from the same period last year.